Quercetin-containing self-nanoemulsifying drug delivery system for improving oral bioavailability.
Quercetin is a dietary flavonoid with potential chemoprotective effects, but has low bioavailability because of poor aqueous solubility and low intestinal absorption. A quercetin-containing self-nanoemulsifying drug delivery system (Q-SNEDDS) was developed to form oil-in-water nanoemulsions in situ for improving quercetin oral bioavailability. On the basis of the quercetin solubility, emulsifying ability, and stability after dispersion in an aqueous phase, an optimal SNEDDS consisting of castor oil, Tween® 80, Cremophor® RH 40, and PEG 400 (20:16:34:30, w/w) was identified. Upon mixing with water, Q-SNEDDS formed a nanoemulsion having a droplet size of 208.8 ± 4.5 nm and zeta potential of -26.3 ± 1.2 mV. The presence of Tween® 80 and PEG 400 increased quercetin solubility and maintained supersaturated quercetin concentrations (5 mg/mL) for >1 month. The optimized Q-SNEDDS significantly improved quercetin transport across a human colon carcinoma (Caco-2) cell monolayer. Fluorescence imaging demonstrated rapid absorption of the Q-SNEDDS within 40 min of oral ingestion. Following oral administration of Q-SNEDDS in rats (15 mg/kg), the area under the concentration curve and maximum concentration of plasma quercetin after 24 h increased by approximately twofold and threefold compared with the quercetin control suspension. These data suggest that this Q-SNEDDS formulation can enhance the solubility and oral bioavailability of quercetin for appropriate clinical application.
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, 06269.
Thanh Huyen
TH
Tran
Yi
Y
Guo
Donghui
D
Song
Richard S
RS
Bruno
Xiuling
X
Lu
D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics; D018938:Caco-2 Cells; D002368:Castor Oil / Q000737:chemistry; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004355:Drug Stability; D045703:Emulsifying Agents / Q000737:chemistry*; D020895:Enterocytes / Q000378:metabolism*; D005079:Excipients / Q000737:chemistry; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D049329:Nanostructures / Q000008:administration & dosage / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry; D011136:Polysorbates / Q000737:chemistry; D011794:Quercetin / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility
D000975:Antioxidants; D045703:Emulsifying Agents; D005079:Excipients; D011136:Polysorbates; C022131:cremophor; D011092:Polyethylene Glycols; D002368:Castor Oil; D011794:Quercetin
absorption; bioavailability; nanoparticle; oral drug delivery; pharmacokinetics; solubility